Suppr超能文献

Sp1样蛋白KLF13与SREBP-Sp1激活复合物之间的新型功能相互作用是低密度脂蛋白受体启动子功能调控的基础。

A novel functional interaction between the Sp1-like protein KLF13 and SREBP-Sp1 activation complex underlies regulation of low density lipoprotein receptor promoter function.

作者信息

Natesampillai Sekar, Fernandez-Zapico Martin E, Urrutia Raul, Veldhuis Johannes D

机构信息

Endocrine Research Unit and Gastroenterology Research Unit, Department of Internal Medicine, Mayo School of Graduate Medical Education, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA.

出版信息

J Biol Chem. 2006 Feb 10;281(6):3040-7. doi: 10.1074/jbc.M509417200. Epub 2005 Nov 22.

Abstract

Cholesterol homeostasis is regulated by a family of transcription factors designated sterol regulatory element-binding proteins (SREBPs). Precise control of SREBP-targeted genes requires additional interactions with co-regulatory transcription factors. In the case of the low density lipoprotein receptor (LDLR), SREBP cooperates with the specificity protein Sp1 to activate the promoter. In this report, we describe a novel pathway in LDLR transcriptional regulation distinct from the SREBP-Sp1 activation complex involving the Sp1-like protein Krueppel-like factor 13 (KLF13). Using a combination of RNA interference, electrophoretic mobility shift, chromatin immunoprecipitation, and reporter assays, deletion, and site-directed mutagenesis, we demonstrated that KLF13 mediates repression in a DNA context-selective manner. KLF13 repression of LDLR promoter activity appears to be needed to keep the receptor silent, a state that can be antagonized by Sp1, SREBP, and inhibitors of histone deacetylase activity. Chromatin immunoprecipitation assay confirmed that KLF13 binds proximal LDLR DNA sequences in vivo and that exogenous oxysterol up-regulates such binding. Together these studies identify a novel regulatory pathway in which gene repression by KLF13 must be overcome by the Sp1-SREBP complex to activate the LDLR promoter. Therefore, these data should replace a pre-existent and more simple paradigm that takes into consideration only the induction of the activator proteins Sp1-SREBP as necessary for LDLR promoter drive without including default repression, such as that by KLF13, of the LDLR gene.

摘要

胆固醇稳态由一类称为固醇调节元件结合蛋白(SREBPs)的转录因子家族调控。对SREBP靶向基因的精确控制需要与共调节转录因子进行额外的相互作用。就低密度脂蛋白受体(LDLR)而言,SREBP与特异性蛋白Sp1协同激活启动子。在本报告中,我们描述了一种不同于涉及Sp1样蛋白Krüppel样因子13(KLF13)的SREBP-Sp1激活复合物的LDLR转录调控新途径。通过结合RNA干扰、电泳迁移率变动分析、染色质免疫沉淀、报告基因检测、缺失和定点诱变,我们证明KLF13以DNA背景选择性方式介导抑制作用。KLF13对LDLR启动子活性的抑制似乎是使受体保持沉默所必需的,而Sp1、SREBP和组蛋白去乙酰化酶活性抑制剂可拮抗这种沉默状态。染色质免疫沉淀分析证实KLF13在体内结合LDLR近端DNA序列,并且外源性氧化固醇上调这种结合。这些研究共同确定了一种新的调控途径,即Sp1-SREBP复合物必须克服KLF13的基因抑制作用才能激活LDLR启动子。因此,这些数据应取代先前存在的、更为简单的模式,该模式仅考虑激活蛋白Sp1-SREBP的诱导是LDLR启动子驱动所必需的,而未包括LDLR基因的默认抑制,如KLF13的抑制作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验